<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03652441</url>
  </required_header>
  <id_info>
    <org_study_id>Uni-Koeln 3263</org_study_id>
    <secondary_id>2018-000873-59</secondary_id>
    <nct_id>NCT03652441</nct_id>
  </id_info>
  <brief_title>Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma</brief_title>
  <official_title>Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is to improve disease control after an allogeneic stem cell
      transplantation (alloSCT) for relapsed or refractory classical Hodgkin lymphoma (rrHL, cHL)
      with consolidation therapy by Brentuximab Vedotin (BV) for up to one year.

      The primary objective of the trial is to show efficacy of the experimental consolidative
      treatment strategy. Secondary objectives are to further evaluate efficacy, show safety and
      feasibility and perform correlative studies.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2019</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year Cumulative incidence of relapse (CIR)</measure>
    <time_frame>1 year</time_frame>
    <description>1-year Cumulative incidence of relapse (CIR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1- and 2-year Progression-free survival (PFS)</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>1- and 2-year Progression-free survival (PFS)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Classical Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Maintenance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brentuximab Vedotin will be administered i.v. at 1.8mg/kg at 3-weekly intervals for up to 16 infusions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brentuximab Vedotin</intervention_name>
    <description>BV will be administered i.v. at 1.8mg/kg at 3-weekly intervals for up to 16 infusions</description>
    <arm_group_label>Maintenance</arm_group_label>
    <other_name>BV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with relapsed/refractory cHL who receive an allogeneic stem cell
             transplantation

          -  Histologically proven cHL in the most recent tumor biopsy

          -  Absolute neutrophil count ≥ 500/mm³

          -  ECOG ≤2

          -  Age ≥ 18 years

        Exclusion Criteria:

          -  Presence of nodular lymphocyte-predominant HL (NLPHL) or grey-zone lymphoma

          -  Progressive disease as last documented response prior to alloSCT

          -  Any peripheral neuropathy ≥ grade 2

          -  Any other serious disease or organ dysfunction which might impair protocol treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christof Scheid, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cologne, I. Dept. of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Fuchs</last_name>
    <phone>+49221478</phone>
    <phone_ext>88200</phone_ext>
    <email>ghsg@uk-koeln.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>1st Department of Medicine, Cologne University Hospital</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Christof Scheid, Prof.</last_name>
      <email>GHSG@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Christof Scheid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Engert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>August 28, 2018</study_first_submitted>
  <study_first_submitted_qc>August 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <last_update_submitted>July 2, 2019</last_update_submitted>
  <last_update_submitted_qc>July 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Christoph Scheid</investigator_full_name>
    <investigator_title>Head of Stem Cell Transplantation</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

